GlassScriptPhysician profile
Pavan Ashok Patel
NPI 1760748156
$11,026.21
in general payments reported to CMS, 2019-2025
39 companies · $2,346 in 2025
The $2,346 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201 · 2020: $456 · 2021: $1,783 · 2022: $1,843 · 2023: $2,362 · 2024: $2,035 · 2025: $2,346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,792 · Travel and Lodging: $830 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,792.33 |
| Travel and Lodging | $829.62 |
| Education | $120.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,728.93 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,247.73 | 2020-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $963.96 | 2020-2025 | |
| Janssen Biotech, INC. | $850.30 | 2021-2025 | Tremfya, Stelara |
| Olympus Corporation of The Americas | $847.75 | 2023 | Single Use Electrosurgical Knife Kd-655, Single Use Electrosurgical Hemostatic Forceps |
| Takeda Pharmaceuticals U.S.A., INC. | $842.24 | 2020-2025 | Entyvio, Eohilia, Gattex |
| Boston Scientific Corporation | $558.26 | 2019-2025 | General - Biliary Devices, Exalt Model D |
| Alnylam Pharmaceuticals INC. | $503.77 | 2020-2025 | Givlaari |
| Genzyme Corporation | $256.25 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $254.99 | 2021-2023 | |
| Celgene Corporation | $241.93 | 2022-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $223.79 | 2022-2023 | Rebyota |
| Amgen INC. | $206.84 | 2020-2022 | |
| Lilly USA, LLC | $178.69 | 2023-2025 | Omvoh |
| Pfizer INC. | $173.49 | 2021-2025 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $166.04 | 2021-2025 | Sucraid |
| Phathom Pharmaceuticals, INC. | $163.87 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $159.67 | 2020-2024 | Ocaliva |
| Cook Medical LLC | $158.96 | 2019-2025 | Hemospray |
| Ironwood Pharmaceuticals, INC | $150.50 | 2020-2025 | Linzess |
| Merck Sharp & Dohme LLC | $128.00 | 2021-2024 | Dificid |
| Regeneron Healthcare Solutions, INC. | $114.42 | 2024-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $112.69 | 2024 | Zeposia |
| Madrigal Pharmaceuticals | $103.18 | 2024-2025 | Rezdiffra, Resmetirom |
| Shionogi INC | $95.62 | 2019 | |
| Ardelyx, INC. | $94.74 | 2022-2024 | Ibsrela |
| Aimmune Therapeutics, INC. | $70.48 | 2024 | |
| Daiichi Sankyo INC. | $66.94 | 2021-2022 | |
| Organon LLC | $64.00 | 2024-2025 | Hadlima |
| Evoke Pharma, INC. | $53.99 | 2021-2025 | |
| Vivus LLC | $49.81 | 2021-2025 | Pancreaze |
| Braintree Laboratories, INC. | $45.43 | 2021-2023 | Suflave |
| Redhill Biopharma INC. | $45.04 | 2021-2022 | |
| Conmed Corporation | $26.41 | 2020 | |
| Celltrion USA INC. | $21.40 | 2024 | Zymfentra |
| Intra-Sana Laboratories | $14.65 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.47 | 2019 | |
| Ethicon US, LLC | $14.21 | 2021 | |
| Shield Therapeutics INC | $12.77 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pavan Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.